increased the production of Silver sulfadiazine and other similar products. The
market in Asia Pacific is still relatively unexplored.
However, countries such as China, India, Australia and Japan are expected to
emerge as new players in the wound care market and are anticipated to serve as
new revenue generators over the forecast period. Silver sulfadiazine is losing its
edge as the major product of this industry as it has lot of undesired side effects due
to which the effectiveness of Silver sulfadiazine is still being debated upon.
Furthermore, the rising price of Silver, which is one of the prime raw materials for
the production of silver sulfadiazine, is a matter of concern. In addition, for
improving synthetic dressing materials, advanced technologies in wound treatment
which include the xenogeneic tissue scaffold, endovascular arterial repair
techniques, endoscopic subfascial ligation of venous perforators, recombinant
growth factors, bilayered human dermal substitutes, and hyperbaric oxygen therapy
is forcing silver sulfadiazine to lose its market importance.
Johnson & Johnson Limited, 3M Company, Baxter International Inc Monarch
Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. are some of the key
players in this market.
Get accurate market forecast and analysis on the Silver Sulfadiazine
Market Request a sample to stay abreast on the key trends impacting this
market.
http://www.transparencymarketresearch.com/sample/sample.php?
flag=B&rep_id=3956
This research report analyzes this market on the basis of its market segments,
major geographies, and current market trends. Geographies analyzed under this
research report include
North America
Asia Pacific
Europe
Rest of the World
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years